About The Study: Glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy in idiopathic intracranial hypertension is associated with significant reductions in medication use, symptoms/signs, and procedural interventions, suggesting its potential as a management strategy. Further prospective studies are warranted to confirm these findings.
Corresponding Author: To contact the corresponding author, Dennis J. Rivet II, MD, email dennis.rivet@vcuhealth.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2025.2020)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.2020?guestAccessKey=6263cb47-e0e9-46cd-a28c-82c223161332&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071425
JAMA Neurology